Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 46 out of 100. Tau biomarkers

Topic: Brain proteins, microglia and lab models

Plain-language summary

Unlabelled The purpose of this study was to investigate the potential relationships between cerebrospinal fluid (CSF) measurements of beta-amyloid-1-42 (Abeta(1-42)) and total tau to (11)C-Pittsburgh compound B ((11)C-PiB) and 2-(1-{6-[(2-(18)F-fluoroethyl)(methyl)amino]-2-naphthyl}ethylidene) malononitrile ((18)F-FDDNP) binding as measured using PET. Methods A total of 37 subjects were included, consisting of 15 patients with Alzheimer disease (AD), 12 patients with mild cognitive impairment, and 10 healthy controls. All subjects underwent a lumbar puncture and PET using both (11)C-PiB and (18)F-FDDNP.

What this study adds

Evidence grade: Low

The record lists 37 participants. This study looked at whether cerebrospinal fluid levels of beta-amyloid-1-42 and total tau relate to brain PET binding of two tracers in patients with Alzheimer disease, mild cognitive impairment, and healthy controls. It is a biomarker correlation study and does not test any treatment, cure, or prevention.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Tolboom, N., van der Flier, W. M., Yaqub, M., Boellaard, R., Verwey, N. A., Blankenstein, M. A., et al. (2009). Relationship of cerebrospinal fluid markers to 11C-PiB and 18F-FDDNP binding. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. https://doi.org/10.2967/jnumed.109.064360

Vancouver

Tolboom N, van der Flier WM, Yaqub M, Boellaard R, Verwey NA, Blankenstein MA, et al. Relationship of cerebrospinal fluid markers to 11C-PiB and 18F-FDDNP binding. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2009. doi:10.2967/jnumed.109.064360. PMID: 19690025.

BibTeX

@article{tolboom2009-19690025,
  author  = {Tolboom, N. and van der Flier, W. M. and Yaqub, M. and Boellaard, R. and Verwey, N. A. and Blankenstein, M. A. and Windhorst, A. D. and Scheltens, P. and others},
  title   = {{Relationship of cerebrospinal fluid markers to 11C-PiB and 18F-FDDNP binding}},
  journal = {Journal of nuclear medicine : official publication, Society of Nuclear Medicine},
  year    = {2009},
  doi     = {10.2967/jnumed.109.064360},
  pmid    = {19690025},
  url     = {https://doi.org/10.2967/jnumed.109.064360}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

This study looked at whether cerebrospinal fluid levels of beta-amyloid-1-42 and total tau relate to brain PET binding of two tracers in patients with Alzheimer disease, mild cognitive impairment, and healthy controls. It is a biomarker correlation study and does not test any treatment, cure, or prevention.

Study details

How this study scored 46/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 2 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 1 of 5; Sample size 1 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 5 of 7; Citations per year 3 of 5; Impact for its field and year 4 of 6; Cited by studies here 3 of 6; Still being cited 0 of 4; Senior author's track record 3 of 4; Institution's track record 1 of 3; Multicenter collaboration 0 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. Total 46 of 100.46 of 100 points earned54 not earned

Published in a peer-reviewed journal. Scored zero for study design, effect reported and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Journal of nuclear medicine : official publication, Society of Nuclear Medicine)
Journal's citation record 2 / 4 Journal of Nuclear Medicine: journal h-index 230 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 1 / 5 2009 — within 20 year(s) of the newest study here
Sample size 1 / 4 37 participants
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 5 / 7 Cited 160 times (OpenAlex, 2026-10-10)
Citations per year 3 / 5 8.4 citations a year over 19 year(s) since 2009
Impact for its field and year 4 / 6 Cited 9.4× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 3 / 6 Cited by 28 other studies in this library
Still being cited 0 / 4 Cited 2 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 3 / 4 Last-listed author Bart N.M. van Berckel: h-index 73 (OpenAlex, whole career)
Institution's track record 1 / 3 Amsterdam UMC Location Vrije Universiteit Amsterdam: institution h-index 938 (OpenAlex)
Multicenter collaboration 0 / 3 OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete)
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 19690025)
Free to read 0 / 2 Behind a paywall — scores zero
Total 46 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Later studies that cite this one

28 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.

Related studies in Tau biomarkers from nearby years

Also tagged “cerebrospinal”

820 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 820 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Tau biomarkers

See all studies in Tau biomarkers →